Virtus ETF Advisers LLC Caribou Biosciences, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.82 - $8.26 $4,632 - $7,937	-961 Reduced 6.4%	14,044 $72,000
Q4 2023 Feb 15, 2024	SELL	$3.58 - $6.25 $22,743 - $39,706	-6,353 Reduced 29.75%	15,005 $85,000
Q3 2023 Nov 07, 2023	SELL	$4.08 - $8.14 $8,682 - $17,321	-2,128 Reduced 9.06%	21,358 $102,000
Q2 2023 Aug 14, 2023	BUY	$4.04 - $5.47 $44,791 - $60,645	11,087 Added 89.42%	23,486 $99,000
Q1 2023 May 15, 2023	SELL	$4.3 - $7.78 $20,493 - $37,079	-4,766 Reduced 27.77%	12,399 $65,000
Q4 2022 Feb 14, 2023	SELL	$5.57 - $11.01 $17,846 - $35,276	-3,204 Reduced 15.73%	17,165 $107,000
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $822 - $1,969	154 Added 0.76%	20,369 $215,000
Q2 2022 Aug 12, 2022	BUY	$5.1 - $9.74 $55,197 - $105,416	10,823 Added 115.24%	20,215 $110,000
Q1 2022 May 16, 2022	SELL	$8.42 - $15.32 $4,689 - $8,533	-557 Reduced 5.6%	9,392 $86,000
Q4 2021 Feb 14, 2022	BUY	$14.59 - $23.26 $145,155 - $231,413	9,949 New	9,949 $150,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.